Boston Therapeutics Elects Dr. Henry Esber to its Board of Directors
Complete the form below to unlock access to ALL audio articles.
Boston Therapeutics, Inc. has announced the election of Dr. Henry J. Esber to its Board of Directors, effective December 20, 2011.
"We are very pleased to have Dr. Esber join our Board of Directors," said David Platt, Ph.D., Chairman of the Board of Directors and Chief Executive Officer of Boston Therapeutics.
Platt continued, "Dr. Esber is a highly regarded executive with extensive drug development and business experience. His expertise is a great addition to the Board of Directors."
"I believe Boston Therapeutics offers the potential to be the leader in diabetes drug development," said Dr. Esber.
Dr. Esber continued, "I am excited to be a part of a team that has a business model which includes near term revenue through sales of over-the-counter products, such as SUGARDOWN™, while developing PAZ320 as a pharmaceutical candidate for management of post-meal blood glucose in diabetics."
